Explore the Agenda
7:15 am Morning Check in & Coffee
7:55 am Chair’s Opening Remarks
Resolution, Scale, & Context: Advancing Drug Discovery with Multiomics & AI in Bowel Disease
8:00 am Does Resolution Depth Still Matter in the Era of Big Data & “Artificial Intelligence”
- What is big data and what is generally considered big data. This section will provide a quick overview of how big data has evolved and how we classify “big data” has changed over time
- Learn about different issues that can limit the utility of genomics data and is normally not considered when aggregating data collections together
- Discover how assumptions made about the biology and the AI/ML methods being employed may lead to possible blind spots for accurate discovery
8:30 am Panel Discussion: Enabling Precision Medicine in IBD Through Advanced Data Collaboratio
- Explore how different stakeholders, clinicians, technology providers, and patient organizations define the role of data collaboration in advancing precision medicine today
- Why is a data-driven precision medicine strategy critical now in IBD, and what are the clinical and patient consequences if collaboration doesn’t happen early enough?
- What are the biggest barriers and opportunities in standardising endpoints, clinical assumptions, metadata, and biospecimen strategies across real-world and clinical trial datasets?
- As AI becomes embedded in drug discovery and development, how does data quality, particularly in real-world versus clinical trial data, limit or enable its impact?
- What practical steps can the ecosystem take to translate collaborative data efforts into actionable precision medicine, from trial design and regulatory strategy to prescribing and patient access?
9:15 am Harnessing Multiomics and Machine Learning to Overcome Metadata Challenges and Build Predictive Biomarker Signatures
- Address logistical and analytical challenges in metadata capture to ensure robust, reproducible linkage between omics data and clinical outcomes
- Discuss how multiomic integration can reflect IBD’s molecular complexity and drive more accurate biomarker discover
- Learn how machine learning approaches can integrate multiomic datasets to identify composite
9:45 am Morning Break & Networking
Transforming Patient Care Through Understanding Disease Complexity & Heterogeneity
10:45 am Targeted PDE4 Inhibition Using PALI-2108 Prodrug as a Novel Therapeutic Strategy in Fibrostenotic Crohn’s Disease
- Highlighting how locally bioactivated pharmacology and translational biomarker science are converging to redefine the treatment of fibrostenotic IBD
11:15 am Unlocking the Power of Clinical Phenotypes to Advance Precision Medicine Targets
- Highlighting stable, well-established features, such as ileal and colonic Crohn’s disease, that correlate with treatment outcomes and complication risk
- Demonstrating how clinical phenotypes could guide patient stratification in clinical trials, identify subpopulations most likely to respond, and optimize therapy selection
- Discussing why precision medicine approaches in IBD have lagged behind oncology, and how aligning research priorities with commercial feasibility can help advance targeted therapies
11:45 am Roundtable Discussion: Delivering Faster & More Reliable IBD Trials Using Real-World Evidence, Smarter Recruitment & Meaningful Endpoints
- Explore innovative recruitment and retention strategies that have successfully reduced trial delays and improved reliability
- Share experiences using real-world data and predictive tools to identify ideal candidates and assess the impact on response rates and trial costs
- Examine how real-world evidence can be strategically applied to design endpoints in IBD trials that are clinically meaningful and aligned with regulatory and commercialization goals
- Address challenges of data fragmentation in IBD research by improving access to comprehensive datasets including biomarkers, histology, and patient-reported outcomes
12:30 pm Lunch Break & Networking
Transforming Clinical Trial Formation Through Biomarker Innovation, Advanced Imaging & Mechanism-Based Endpoints
1:30 pm Understanding Tissue Mechanisms of Reduced Drug Response & Pathological Complexities to Help Improved Management of IBD Patients
- Recent mechanistic evidence on drug effect, overcoming drug-resistance and therapeutic non-response in IBD
- Unmet need: Fibrotic complications in CD and highlighting underlying cellular complexity
- Ways to monitor fibrosis in CD to help patient stratification and improve drug efficacy
2:00 pm Integrating Imaging-Based Biomarkers to Advance Precision in IBD Clinical Trials
- Maximizing the value of endoscopy by driving consistency in centralized reads
- Opportunities and challenges with deploying MRI based biomarkers in global clinical trials
- Emerging opportunities for AI tools to automate and accelerate central reviews
2:30 pm Using Blood-Based Epigenetic Signatures to Personalize First-Line Biologic Therapy in Crohn’s Disease
- Investigating a scalable, blood-derived DNA methylation panel designed to guide first-line biologic selection at diagnosis, aiming to move beyond today’s trial-and-error paradigm and reduce early complications linked to ineffective therapy
- Leveraging a validated epigenetic algorithm undergoing testing in the OMICRON clinical trial to improve therapeutic success rates
- Establishing a blueprint for cross-disease precision medicine, with methylation markers and machine-learning pipelines engineered for translation